Daniel A. Pollyea, University of Colorado Anschutz Medical Campus (IMAGE)

University of Colorado Anschutz Medical Campus

Daniel A. Pollyea, University of Colorado Anschutz Medical Campus

Caption

At ASCO 2018, Daniel A. Pollyea, MD, MS presents positive results for phase 1 trial of ivosidenib against AML.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.